Volume : VI, Issue : IV, April - 2017

Abstract :

 Non–steroidal anti–inflammatory drugs are the only therapeutic option available at present for the treatment of pyrexia. The greatest disadvantage of using the presently Non–steroidal anti–inflammatory drug is that they cause gastrointestinal irritation and reappearance of symptoms after discontinuation. Therefore, there is a dire need for screening and development of novel, but better antipyretic drugs. Coumarins have multiple biological activities; various coumarin–related derivatives are recognized as inhibitors of the lipoxygenase and cycloxygenase pathways of arachidonate metabolism. Several natural or synthetic coumarins with various hydroxyl and other substitutes were found to inhibit lipid peroxidation and to scavenge hydroxyl radical and superoxide anion and to influence processes involving free radical mediated injury. The objective of the present study was to evaluate the antipyretic activity of various heterocyclic derivatives of 3–formyl–4–hydoxycoumarin (synthesized by us) in animal models. All compounds synthesized were evaluated for the above activity and their effects were compared with the standard drugs. In our study, a new model of pyrexia suggested by Tomazetti et al., 2005 was used where backer’s yeast is used to induced pyrexia in juvenile male Wistar rats, the rats received Backer’s yeast at 135mg/kg intraperitonealy. The test compound or Paracetamol was given orally 1 hour after injection of yeast (when average rise in rectal temp was about 1ºC).  The test compounds (heterocyclic derivatives of 3–formyl–4–hydoxycoumarin) showed significant antipyretic activity in mice.

Article: Download PDF    DOI : https://www.doi.org/10.36106/paripex  

Cite This Article:

, GLOBAL JOURNAL FOR RESEARCH ANALYSIS : Volume-2 | Issue-2 | February-2013

Number of Downloads : 561

References :